Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | DDO | Q99489 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24554903 | 0.81 | DAO (0.49) | DAODDOCA12CA9NR3C1 | |
| SCHEMBL24554894 | 0.81 | DAO (0.53) | DAODDOCA12CA9NR3C1 | |
| SCHEMBL12829820 | 0.79 | DAO (0.50) | DAOCA12CA9HRH4PCSK9 | |
| SCHEMBL17345813 | 0.79 | DAO (0.50) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL5675106 | 0.78 | CA12 (0.46) | DAODDOCA12CA9HRH4 | |
| SCHEMBL20853015 | 0.75 | TNF (0.44) | DAOAR | |
| SCHEMBL24451612 | 0.75 | PARP1 (0.39) | HRH4PARP1LMNA | |
| SCHEMBL3293424 | 0.75 | DAO (0.53) | DAODDOCA12CA9HRH4 | |
| SCHEMBL28908108 | 0.74 | ALDH1A1 (0.49) | DAOPARP1KDM4EALDH1A1MAPT | |
| SCHEMBL27336454 | 0.74 | NR3C1 (0.43) | DAONR3C1NR3C2PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | DAO 727/4885DDO 2271/4885CA12 4008/4885 |
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | DAO 2990/4885DDO 3628/4885CA12 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.